GET DAILY SIGNALSEndovia Health Sciences (EDVA): A Micro-Cap Shift Toward Cannabinoid-Based Therapeutics
Key Takeaways
- EDVA is the NYSE American ticker for Endovia Health Sciences, Inc., a micro-cap healthcare company headquartered in Fort Lauderdale, Florida.
- The company was formerly known as Splash Beverage Group, Inc. and adopted the Endovia Health Sciences name and EDVA ticker effective August 24, 2026.
- Endovia is repositioning itself as a diversified, cannabinoid-based health sciences platform spanning pharmaceutical, veterinary, and consumer wellness markets.
- Its lead program is CannEpil, a pharmaceutical-grade formulation of CBD and THC isolates developed as an epilepsy therapy.
- The company is early-stage, generates minimal revenue, and has disclosed ongoing financing and listing-compliance challenges.
Introduction
Endovia Health Sciences, Inc. is a small healthcare company working to move beyond its beverage roots and establish itself in the regulated space of cannabinoid-based medicine. Investors track EDVA as a high-risk, early-stage opportunity tied to the commercialization of cannabis-derived pharmaceuticals and wellness products for both human and animal health markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Company Background
Endovia Health Sciences, Inc. is incorporated in Nevada with its headquarters in Fort Lauderdale, Florida. The company’s history includes predecessor entities that operated across various industries, most recently as Splash Beverage Group, Inc., which traded on the NYSE American under the ticker SBEV.
In August 2026, the company changed its name to Endovia Health Sciences and began trading under the EDVA symbol. This reflects a deliberate move away from legacy beverage operations toward a cannabinoid-focused health sciences platform. The stated goal is to translate science into regulated therapies and trusted wellness products for people and animals.
Business Strategy and Market Focus
Endovia’s approach centers on three main areas:
- Commercial pharmaceutical assets: advancing differentiated, cannabinoid-based products through international distribution and partnerships.
- FDA-regulated therapeutics: progressing human and veterinary cannabinoid therapies along established U.S. regulatory routes.
- Consumer wellness and beverages: developing cannabinoid-based wellness and beverage options as regulations and opportunities allow.
The flagship product, CannEpil, is a pharmaceutical-grade oral liquid that combines CBD and THC isolates and is positioned as an epilepsy therapy. The company has initiated early regulatory steps, including opening an Investigational New Animal Drug file with the FDA’s Center for Veterinary Medicine for a veterinary program. Endovia has noted commercial interests in markets such as Ireland, the United Kingdom, Australia, and Latin America. From what I see, the company remains early-stage with minimal revenue and a small team, so its competitive position is still unproven against larger players in the sector.
Investor Interest in EDVA
Attention to EDVA stems mainly from the long-term potential of regulated cannabis and cannabinoid pharmaceuticals. Investors typically evaluate whether the CannEpil program and overall platform can reach meaningful regulatory and commercial milestones. Key potential drivers include pursuit of FDA pathways for human and veterinary therapies, rights to CannEpil, and possible international partnerships. For risk-tolerant investors, the appeal lies in the transformation narrative and the stock’s sensitivity to news on regulatory progress, financing, and strategic moves.
Risks to Consider
Endovia faces several notable risks that warrant close attention:
- Going-concern and liquidity risk: Limited cash has already restricted development activities, and additional capital will be needed to continue operations.
- Listing-compliance risk: The company has received notices from NYSE American regarding continued listing standards, including stockholders’ equity requirements, with no guarantee of regaining compliance. Trading was temporarily halted in July 2026 after the share price fell below the exchange’s low-price threshold.
- Regulatory uncertainty: Cannabinoid therapeutics operate under evolving rules in the U.S. and internationally, and approvals are not assured.
- Early-stage operations: Minimal revenue, a very small workforce, and a portfolio that has yet to achieve broad commercial traction.
- Micro-cap volatility and dilution: These stocks can be highly volatile and illiquid; the company has completed a reverse stock split and may pursue dilutive financing.
Conclusion
Endovia Health Sciences (EDVA) represents an early-stage micro-cap company undergoing a strategic reinvention from beverage operations into the heavily regulated cannabinoid-medicine field. Its profile centers on the CannEpil program, the three-part platform strategy, and ambitions in pharmaceutical and wellness markets. The potential upside exists, yet it is balanced by substantial financing, regulatory, and listing risks that keep the investment highly speculative.
AI-Powered Research Tools
In my own work, I often turn to Tickeron’s AI Screener when evaluating micro-cap names like this one. The platform lets users apply technical indicators, fundamentals, volatility filters, AI signals, and custom criteria to scan thousands of stocks and ETFs quickly. It has become a practical part of my routine for surfacing ideas that align with specific strategies and for comparing opportunities across industries.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
EDVA's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for EDVA turned positive on October 06, 2026. Looking at past instances where EDVA's MACD turned positive, the stock continued to rise in 33 of 38 cases over the following month. The odds of a continued upward trend are 87%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where EDVA's RSI Indicator exited the oversold zone, 42 of 49 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on October 23, 2026. You may want to consider a long position or call options on EDVA as a result. In 64 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 82%.
Following a +5.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDVA advanced for three days, in 165 of 193 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDVA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for EDVA entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 8 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 51 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.084) is normal, around the industry mean (3.482). P/E Ratio (-0.008) is within average values for comparable stocks, (-1.183). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (10.695) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 66 (best 1 - 100 worst), indicating steady price growth. EDVA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDVA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement